Relative safety profiles of high dose statin regimens

References

• ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research GroupThe Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT)JAMA20022882998300712479764
   PubMed Web of Science ®Google Scholar
• Alsheikh-AliAAMaddukuriPVHanHEffect of the magnitude of lipid lowering on risk of elevated liver enzymes, rhabdomyolysis, and cancer: insights from large randomized statin trialsJ Am Coll Cardiol2007504091817662392
   PubMed Web of Science ®Google Scholar
• ArmitageJThe safety of statins in clinical practiceLancet2007370960117819017559928
   PubMed Web of Science ®Google Scholar
• AshtonELiewDKrumHShould patients with chronic heart faliure be treated with “statins”?Heart Fail Monit20033828612634877
   PubMedGoogle Scholar
• BallantyneCMCorsiniADavidsonMHRisk for myopathy with statin therapy in high-risk patientsArch Intern Med20031635536412622602
   PubMed Web of Science ®Google Scholar
• BaysHStatin safety: an overview and assessment of the data-2005Am J Cardiol2006976C26C
   PubMed Web of Science ®Google Scholar
• BarriosVAmabileNPaganelliFLipid-altering efficacy of switching from atorvastatin 10 mg/day to ezetimibe/simvastatin in hypercholesterolaemic patients with atherosclerosis or coronary artery diseaseInt J Clin Pract20055913778616351668
   PubMed Web of Science ®Google Scholar
• BarriosVEscobarCCalderonACardiovascular risk profile and risk stratification of the hypertensive population attended by general practitioners and specialists in Spain. The CONTROLRISK studyJ Hum Hypertens2007214798517314997
   PubMed Web of Science ®Google Scholar
• BrassLMAlbertsMJSparksLAn assessment of statin safety by neurologistsAm J Cardiol200697suppl 8A86C88C
   PubMed Web of Science ®Google Scholar
• CannonCPBraunwaldEMcCabeCHIntensive versus moderate lipid lowering with statins after acute coronary syndromesN Engl J Med2004350149550415007110
   PubMed Web of Science ®Google Scholar
• CannonCPSteinbergBAMurphySAMeta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapyJ Am Coll Cardiol2006484384516875966
   PubMed Web of Science ®Google Scholar
• CelikTIyisoyAYukselUCThe panacea for cardiovascular diseases: The role of statins in the management of heart failureInt J Cardiol200788 Epub ahead of print
   Web of Science ®Google Scholar
• ChanPSNallamothuBKGurmHSIncremental benefit and cost-effectiveness of high-dose statin therapy in high-risk patients with coronary artery diseaseCirculation2007115239840917452609
   PubMed Web of Science ®Google Scholar
• Cholesterol Treatment Trialists’ (CTT) CollaboratorsEfficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statinsLancet200536612677816214597
   PubMed Web of Science ®Google Scholar
• Christopher-StineLStatin myopathy: an updateCurr Opin Rheumatol2006186475317053514
   PubMed Web of Science ®Google Scholar
• CohenDEAnaniaFAChalasaniNAn assessment of statin safety by hepatologistsAm J Cardiol200697suppl 8A77C81C16377288
   PubMed Web of Science ®Google Scholar
• Crestor (rosuvastatin calcium) [prescribing information]. August 2005. Accessed April 2006. URL: http://www.astrazeneca-us.com/pi/crestor.pdf
   Google Scholar
• DavidsonMHControversy surrounding the safety of cerivastatinExpert Opin Drug Saf200212071212904136
   PubMedGoogle Scholar
• DaleKMWhiteCMHenyanNNImpact of statin dosing intensity on transaminase and creatine kinaseAm J Med20071207061217679130
   PubMed Web of Science ®Google Scholar
• DavidsonMHClarkJAGlassLMStatin safety: an appraisal from the Adverse Event Reporting System (AERS)Am J Cardiol200697suppl 8A32C43C
   PubMed Web of Science ®Google Scholar
• DavidsonMHRobinsonJGSafety of aggressive lipid managementJ Am Coll Cardiol20074917536217466224
   PubMed Web of Science ®Google Scholar
• de LemosJABlazingMAWiviottSDEarly intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trialJAMA200429213071615337732
   PubMed Web of Science ®Google Scholar
• DirksAJJonesKMStatin induced apoptosis and skeletal myopathyAm J Physiol Cell Physiol2006291120812
   PubMed Web of Science ®Google Scholar
• DownsJRClearfieldDOWeisSPrimary prevention of acute coronary events with lovastatin in men and women with average cholesterol levelsJAMA19982791615229613910
   PubMed Web of Science ®Google Scholar
• ErginAMuntnerPSherwinRSecular trends in cardiovascular disease mortality, incidence, and case fatality rates in adults in the United StatesAm J Med20041172192715308430
   PubMed Web of Science ®Google Scholar
• Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in AdultsExecutive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)JAMA200128524869711368702
   PubMed Web of Science ®Google Scholar
• GaistDGarcia RodriguezLAHuertaCAre users of lipid-lowering drugs at increased risk of peripheral neuropathy?Eur J Clin Pharmacol2001569313311317483
   PubMed Web of Science ®Google Scholar
• GersonRJMacDonaldJSAlbertsAWOn the etiology of subcapsular lenticular opacities produced in dogs receiving HMG-CoA reductase inhibitorsExp Eye Res19905065782307197
   PubMed Web of Science ®Google Scholar
• GrundySMCleemanJIMerzCNImplications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelinesCirculation20041102273915249516
   PubMed Web of Science ®Google Scholar
• HarperCRJacobsonTAThe broad spectrum of statin myopathy: from myalgia to rhabdomyolysisCurr Opin Lipidol200718401817620856
   PubMed Web of Science ®Google Scholar
• Heart Protection Study Collaborative GroupMRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trialLancet200236072212114036
   PubMed Web of Science ®Google Scholar
• Heart Protection Study Collaborative GroupEffects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20,536 people with cerebrovascular disease or other high-risk conditionsLancet20043637576715016485
   PubMed Web of Science ®Google Scholar
• HermannMBogsrudMPMoldenEExposure of atorvastatin is unchanged but lactone and acid metabolites are increased several-fold in patients with atorvastatin-induced myopathyClin Pharmacol Ther2006795323916765141
   PubMed Web of Science ®Google Scholar
• HorvathRSchneideratPSchoserBGCoenzyme Q10 deficiency and isolated myopathyNeurology200666253516434667
   PubMed Web of Science ®Google Scholar
• HorwichTBHamiltonMAMaclellanWRLow serum total cholesterol is associated with marked increase in mortality in advanced heart faliureJ Card Fail200282162412397569
   PubMed Web of Science ®Google Scholar
• HultenEJacksonJLDouglasKThe effect of early, intensive statin therapy on acute coronary syndrome: a meta-analysis of randomized controlled trialsArch Intern Med200616618142117000936
   PubMed Web of Science ®Google Scholar
• JacobsonTAStatin safety: lessons from new drug applications for marketed statinsAm J Cardio200697suppl44C51C
   PubMedGoogle Scholar
• KasiskeBLWannerCO’NeillWCAn assessment of statin safety by nephrologistsAm J Cardiol200697suppl 8A82C85C
   PubMed Web of Science ®Google Scholar
• KhushKKWatersDDBittnerVEffect of high-dose atorvastatin on hospitalizations for heart failure: subgroup analysis of the Treating to New Targets (TNT) studyCirculation20071155768317261662
   PubMed Web of Science ®Google Scholar
• KjekshusJApetreiEBarriosVRosuvastatin in older patients with systolic heart failureN Engl J Med200735722486117984166
   PubMed Web of Science ®Google Scholar
• KrumHMcMurrayJJStatins and chronic heart failure: do we need a large-scale outcome trial?J Am Coll Cardiol2002821624
   Google Scholar
• KuulasmaaKTunstall-PedoeHDobsonAEstimation of contribution of changes in classic risk factors to trends in coronary-event rates across the WHO MONICA Project populationsLancet20003556758710703799
   PubMed Web of Science ®Google Scholar
• LaRosaJCGrundySMWatersDDIntensive lipid lowering with atorvastatin in patients with stable coronary diseaseN Engl J Med200535214253515755765
   PubMed Web of Science ®Google Scholar
• Lipitor (atorvastatin calcium) [prescribing information]. September 2005. Accessed April 2006. URL: http://www.pfizer.com/pfizer/download/uspi_lipitor.pdf
   Google Scholar
• McKenneyJMDavidsonMHJacobsonTAFinal conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task ForceAm J Cardiol20069789C94C
   PubMed Web of Science ®Google Scholar
• MenottiAKromhoutDBlackburnHForty-year mortality from cardiovascular diseases and all causes of death in the US Railroad cohort of the Seven Countries StudyEur J Epidemiol2004194172415233313
   PubMed Web of Science ®Google Scholar
• MorganREPalinkasLABarrett-ConnorELPlasma cholesterol and depressive symptoms in older menLancet19933417598093404
   PubMed Web of Science ®Google Scholar
• NichollsSJTuzcuEMSipahiIStatins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosisJAMA200729749950817284700
   PubMed Web of Science ®Google Scholar
• NissenSETuzcuEMSchoenhagenPEffect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trialJAMA200429110718014996776
   PubMed Web of Science ®Google Scholar
• OkrainecKBanerjeeDKEisenbergMJCoronary artery disease in the developing worldAm Heart J200414871515215786
   PubMed Web of Science ®Google Scholar
• OlssonAGSchwartzGGSzarekMEffects of high-dose atorvastatin in patients > or =65 years of age with acute coronary syndrome (from the myocardial ischemia reduction with aggressive cholesterol lowering [MIRACL] study)Am J Cardiol2007996323517317362
   PubMed Web of Science ®Google Scholar
• PaivaHThelenKMVanCRHigh dose statins and skeletal muscle metabolism in humans: a randomized, controlled trialClin Pharm Ther2005786068
   PubMed Web of Science ®Google Scholar
• PasternacRCSmithSCBairey-merzCNACC/AHA/NHLBI clinical advisory on the use and safety of statinsJ Am Col Cardiol20024056772
   PubMed Web of Science ®Google Scholar
• PedersenTRFaergemanOKasteleinJJHigh-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trialJAMA200529424374516287954
   PubMed Web of Science ®Google Scholar
• RainaAPickeringTShimboDStatin use in heart failure: a cause for concern?Am Heart J2006152394916824830
   PubMed Web of Science ®Google Scholar
• RauchhausMClarkALDoehnerWThe relationship between cholesterol and survival in patients with chronic heart faliureJ Am Coll Cardiol200342199340
   Web of Science ®Google Scholar
• RosserWWApplication of evidence from randomised controlled trials to general practiceLancet19993536616410030347
   PubMed Web of Science ®Google Scholar
• SciricaBMMorrowDACannonCPIntensive statin therapy and the risk of hospitalization for heart failure after an acute coronary syndrome in the PROVE IT-TIMI 22 studyJ Am Coll Cardiol20064723263116750703
   PubMedGoogle Scholar
• SeverPSDahlofBPoulterNRPrevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial–Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trialLancet200336111495812686036
   PubMed Web of Science ®Google Scholar
• ShepherdJBlauwGJMurphyMBPravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. PROspective Study of Pravastatin in the Elderly at RiskLancet200236016233012457784
   PubMed Web of Science ®Google Scholar
• StaffaJAChangJGreenICerivastatin and reports of fatal rhabdomyolysisN Engl J Med20023465394011844864
   PubMed Web of Science ®Google Scholar
• StegPGLopez-SendonJLopez de SaEExternal validity of clinical trials in acute myocardial infarctionArch Intern Med2007167687317210880
   PubMedGoogle Scholar
• US Food and Drug Administration. Baycol Supplementary NDA (0.8 mg dose). FDA Medical Review. Cited July 19, 2000. [US Food and Drug Administration Web site.] Accessed August 30, 2005. URL: http://www.fda.gov/cder/foi/nda/2000/20-740S008_Baycol_medr.pdf
   Google Scholar
• WagstaffLRMittonMWArvikBMStatin-associated memory loss: analysis of 60 case reports and review of the literaturePharmacotherapy2003238718012885101
   PubMed Web of Science ®Google Scholar
• WardleJArmitageJCollinsRRandomised placebo controlled trial of effect on mood of lowering cholesterol concentration. Oxford Cholesterol Study GroupBMJ19963137588688757
   PubMedGoogle Scholar
• WengerNKLewisSJHerringtonDMOutcomes of using high- or low-dose atorvastatin in patients 65 years of age or older with stable coronary heart diseaseAnn Intern Med20071471917606955
   PubMed Web of Science ®Google Scholar
• WestwoodFRBigleyARandallKStatin induced muscle necrosis in the rat: distribution, development, and fibre selectivityToxicol Pathol2005332465715902968
   PubMed Web of Science ®Google Scholar
• Zocor (simvastatin) [prescribing information]. August 2005. Accessed December 2005 URL: http://www.merck.com/product/usa/pi_circulars/z/zocor/zocor_pi.pdf
   Google Scholar